,3 Beyond genetic drivers, the persistence of hematopoietic stem cell (HSC) gene expression programs contributes to AML aggressiveness and relapse.4, 5, 6, 7 Although therapies such as venetoclax8 and menin inhibitors9 target leukemia stem cells, few restore differentiation programs,9 as shown in acute promyelocytic leukemia (APL).10 Here, MEN1 is linked to acute promyelocytic leukemia.